Persistence of Vaccine‐Derived Polioviruses among Immunodeficient Persons with Vaccine‐Associated Paralytic Poliomyelitis
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
To estimate long-term poliovaccine virus persistence among immunodeficient patients with vaccine-associated paralytic poliomyelitis (iVAPP), cases reported in the United States during 1975-1997 were reviewed, with subsequent follow-up and virological testing. Six (16.2%) of 37 subjects excreted poliovaccine viruses for > or =6 months. Partial genomic sequencing of their available poliovirus isolates showed considerable divergence from the prototype Sabin strain in all cases. Poliovirus persistence declined over time since the last oral poliovaccine dose: at 6 months, 19.4%; 1 year, 14.3%; 5 years, 4%; and 10 years, 0% (P<.05) of patients. Despite the high prevalence of poliovaccine virus persistence among patients with iVAPP, this group appears to be an unlikely source of poliovirus reintroduction in developed countries because of the rarity and high fatality rate of iVAPP and the possible spontaneous clearance of polioviruses. These results are important for developing "endgame" strategies for the Global Poliomyelitis Eradication Program.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent reports describing highly divergent VDPVs associated with chronic poliovirus infections (10, 69, 88, 90, 113, 123, 216, 223) or with polio outbreaks (84, 169, 177, 226) underscored the earlier concerns and challenged the critical assumption that OPV-derived viruses would not long persist in the community.”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
In the citing paper
“iVAPP differs markedly from VAPP in immunocompetent individuals, as it is rarely associated with Sabin 3 (14% of cases) and is more frequently associated with Sabin 1 (31% of cases) and Sabin 2 (72% of cases) (some patients were infected with more than one serotype) (90).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
In the citing paper
“On the other hand, persons with T-cell immunodeficiencies, including those infected with HIV, do not appear to be at an elevated risk for VAPP (74, 90, 183, 186).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
In the citing paper
“Persons with primary B-cell immunodeficiencies (see below) (168) should not be given OPV because they are at a much higher ( ∼ 3000-fold) risk for VAPP (90, 186).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
In the citing paper
“A much smaller proportion ( ∼ 16%) of iVAPP patients become long-term excretors of iVDPVs (90).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600
Self-citationChronic Enteroviral Meningoencephalitis in Agammaglobulinemic Patients
McKinney, R. E., Katz, S. L., & Wilfert, C. M. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.2.334 · Cited by 452
Treatment of Potentially Life-Threatening Enterovirus Infections with Pleconaril
Rotbart, H. A., Webster, A. D., & for the Pleconaril Treatment Registry Group (2001) · Clinical Infectious Diseases · doi:10.1086/318452 · Cited by 373
Fine, P. E. M., & Carneiro, I. A. M. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009924 · Cited by 247
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2893-2899.1998 · Cited by 213
Self-citationKilpatrick, D. R., Nottay, B., Yang, C. F., Yang, S. J., Mulders, M. N., Holloway, B. P., Pallansch, M. A., & Kew, O. M. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.12.2990-2996.1996 · Cited by 172
Self-citation(2000) · PsycEXTRA Dataset · doi:10.1037/e548082006-001 · Cited by 163
Self-citationChronic progressive poliomyelitis secondary to vaccination of an immunodeficient child
Davis, L. E., Bodian, D., Price, D., Butler, I. J., & Vickers, J. H. (1977) · New England Journal of Medicine · doi:10.1056/nejm197708042970503 · Cited by 155
Detection and identification of vaccine-related polioviruses by the polymerase chain reaction
Yang, C.-F., De, L., Holloway, B. P., Pallansch, M. A., & Kew, O. M. (1991) · Virus Research · doi:10.1016/0168-1702(91)90107-7 · Cited by 144
Self-citationPleconaril: a novel antipicornaviral drug
Romero, J. R. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.2.369 · Cited by 131
Cited by
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Self-citationBurns, C. C., Diop, O. M., Sutter, R. W., & Kew, O. M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu295 · Cited by 309
Self-citationCirculating vaccine-derived polioviruses: current state of knowledge.
Kew, O. M., Wright, P. F., Agol, V. I., Delpeyroux, F., Shimizu, H., Nathanson, N., & Pallansch, M. A. (2004) · PubMed · doi:10.1590/s0042-96862004000100006 · Cited by 258
“Occasionally, immunodeficient persons exposed to OPV become chronically infected ( 9–11 ), excreting derivatives of the OPV strains for many months or years ( 1, 12–14 ).”
Self-citationCirculation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993
Yang, C.-F., Naguib, T., Yang, S.-J., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8366-8377.2003 · Cited by 233
Self-citationVaccine-Acquired Rotavirus in Infants with Severe Combined Immunodeficiency
Patel, N. C., Hertel, P. M., Estes, M. K., de la Morena, M., Petru, A. M., Noroski, L. M., Revell, P. A., Hanson, I. C., Paul, M. E., Rosenblatt, H. M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904485 · Cited by 216
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2893-2899.1998 · Cited by 213
Self-citationDomingo, E. (2010) · Veterinary Research · doi:10.1051/vetres/2010010 · Cited by 183
“Viral population numbers can be largely amplified in immunocompromised individuals, that have been termed ''super-shedders'' or ''super-spreaders'', and constitute large reservoirs of variant viruses [27, 38, 65, 68, 72, 76] .”
BackgroundRisks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication
Tebbens, R. J. D., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Jafari, H., Cochi, S. L., Sutter, R. W., Aylward, R. B., & Thompson, K. M. (2006) · Risk Analysis · doi:10.1111/j.1539-6924.2006.00827.x · Cited by 174
“Although HIV currently represents the most prevalent form of immunodeficiency, particularly in developing countries, no known iVDPV excretors exist among HIVinfected persons and the risk of prolonged excretion appears low.(28,71,122)”
BackgroundSelf-citationBurns, C. C., Campagnoli, R., Shaw, J., Vincent, A., Jorba, J., & Kew, O. (2009) · Journal of Virology · doi:10.1128/jvi.00508-09 · Cited by 170
Self-citationSutter, R. W., Kew, O. M., & Cochi, S. L. (2008) · Vaccines · doi:10.1016/b978-1-4160-3611-1.50030-1 · Cited by 167
Self-citationKim, K.-S., Tracy, S., Tapprich, W., Bailey, J., Lee, C.-K., Kim, K., Barry, W. H., & Chapman, N. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.11.7024-7041.2005 · Cited by 152
Martín, J., Dunn, G., Hull, R., Patel, V., & Minor, P. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3001-3010.2000 · Cited by 160
Burns, C. C., Shaw, J., Jorba, J., Bukbuk, D., Adu, F., Gumede, N., Pate, M. A., Abanida, E. A., Gasasira, A., Iber, J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02954-12 · Cited by 153
Self-citationShulman, L. M., Manor, Y., Handsher, R., Delpeyroux, F., McDonough, M. J., Halmut, T., Silberstein, I., Alfandari, J., Quay, J., Fisher, T., et al. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.10.3729-3734.2000 · Cited by 109
Self-citationTransmission of Imported Vaccine‐Derived Poliovirus in an Undervaccinated Community in Minnesota
Alexander, J. P., Ehresmann, K., Seward, J., Wax, G., Harriman, K., Fuller, S., Cebelinski, E. A., Chen, Q., Jorba, J., Kew, O. M., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/596052 · Cited by 99
“Many case subjects have died of their underlying immunodeficiency, and some have spontaneously cleared their infection [36].”
BackgroundSelf-citationYang, C.-F., Chen, H.-Y., Jorba, J., Sun, H.-C., Yang, S.-J., Lee, H.-C., Huang, Y.-C., Lin, T.-Y., Chen, P.-J., Shimizu, H., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.12623-12634.2005 · Cited by 106
“In such settings, the occurrence of chronic iVDPV infections is rare even among patients with B-cell immunodeficiencies, and most chronically infected patients either spontaneously cease iVDPV excretion or die from complications of their immunodeficiency (37).”
BackgroundInfluentialSelf-citationVaccine-Derived Poliomyelitis 12 Years after Infection in Minnesota
DeVries, A. S., Harper, J., Murray, A., Lexau, C., Bahta, L., Christensen, J., Cebelinski, E., Fuller, S., Kline, S., Wallace, G. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008677 · Cited by 88
Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains
Laassri, M., Lottenbach, K., Belshe, R., Wolff, M., Rennels, M., Plotkin, S., & Chumakov, K. (2005) · The Journal of Infectious Diseases · doi:10.1086/498172 · Cited by 85
Sutter, R. W., Kew, O. M., Cochi, S. L., & Aylward, R. B. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00035-5 · Cited by 85
Self-citationPliaka, V., Kyriakopoulou, Z., & Markoulatos, P. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.28 · Cited by 85
Feasibility of Quantitative Environmental Surveillance in Poliovirus Eradication Strategies
Lodder, W. J., Buisman, A., Rutjes, S. A., Heijne, J. C. M., Teunis, P. F. M., & Husman, A. D. R. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.07972-11 · Cited by 78
“Vulnerable groups within a population such as vaccinated-but-immunodeficient individuals may contribute to poliovirus circulation because of prolonged shedding (20, 21, 28).”
BackgroundAlgorithm to assess causality after individual adverse events following immunizations
Halsey, N. A., Edwards, K. M., Dekker, C. L., Klein, N. P., Baxter, R. P., LaRussa, P. S., Marchant, C. D., Slade, B. A., & Vellozzi, C. J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.005 · Cited by 74
Chan, H., Xiao, Y., Weldon, W. C., Oberste, S. M., Chumakov, K., & Daniell, H. (2016) · Plant Biotechnology Journal · doi:10.1111/pbi.12575 · Cited by 73
Toscana Virus and Acute Meningitis, France
Peyrefitte, C. N., Devetakov, I., Pastorino, B. A. M., Villeneuve, L., Bessaud, M., Stolidi, P., Depaquit, J., Segura, L., Gravier, P., Tock, F., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1105.041122 · Cited by 72
Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses
Thompson, K. M., Pallansch, M. A., Tebbens, R. J. D., Wassilak, S. G. F., & Cochi, S. L. (2012) · Risk Analysis · doi:10.1111/j.1539-6924.2012.01891.x · Cited by 70
Self-citationGuo, J., Bolivar-Wagers, S., Srinivas, N., Holubar, M. K., & Maldonado, Y. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.01.018 · Cited by 71
“The majority (11/13) of deaths were reported to be due to the patient's PID, and only two cases were specified to be a result of paralytic poliomyelitis [44,45].”
BackgroundMethodIsolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child
Adu, F., Iber, J. C., Bukbuk, D. N., Gumede, N., Yang, S.-J., Jorba, J. C., Campagnoli, R. P., Sule, W. F., Yang, C.-F., Burns, C. C., et al. (2007) · Virus Research · doi:10.1016/j.virusres.2007.03.009 · Cited by 70
Self-citationA case for developing antiviral drugs against polio
Collett, M. S., Neyts, J. H., & Modlin, J. F. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.04.002 · Cited by 69
Kamboj, M., & Sepkowitz, K. A. (2007) · Infection Control and Hospital Epidemiology · doi:10.1086/517952 · Cited by 69
Mechanisms of genetic variation in polioviruses
Savolainen‐Kopra, C., & Blomqvist, S. (2010) · Reviews in Medical Virology · doi:10.1002/rmv.663 · Cited by 67
Poliovirus Infections in Four Unvaccinated Children--Minnesota, August-October 2005
(2005) · JAMA · doi:10.1001/jama.294.21.2689 · Cited by 61
Cherkasova, E. A., Yakovenko, M. L., Rezapkin, G. V., Korotkova, E. A., Ivanova, O. E., Eremeeva, T. P., Krasnoproshina, L. I., Romanenkova, N. I., Rozaeva, N. R., Sirota, L., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.2.1062-1070.2005 · Cited by 55
“Paralytic disease in immunodeficient patients following their vaccination with OPV has been recognized for a long time (12, 41), but only during the past decade has the phenomenon received the deserved scrutiny (1, 2, 5, 15, 16, 22, 24, 28, 30).”
BackgroundShaghaghi, M., Soleymanjahi, S., Abolhassani, H., Yazdani, R., Azizi, G., Rezaei, N., Barbouche, M., McKinlay, M. A., & Aghamohammadi, A. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.059 · Cited by 53
Vaccine-associated Paralytic Poliomyelitis in Immunodeficient Children, Iran, 1995–2008
Shahmahmoodi, S., Mamishi, S., Aghamohammadi, A., Aghazadeh, N., Tabatabaie, H., Gooya, M. M., Zahraei, S. M., Mousavi, T., Yousefi, M., Farrokhi, K., et al. (2010) · Emerging infectious diseases · doi:10.3201/eid1607.091606 · Cited by 49
“Immunodefi cient OPV vaccine recipients are potential reservoirs for neurovirulent polio virus reintroduction into the population (8).”
BackgroundTebbens, R. J. D., Pallansch, M. A., & Thompson, K. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1115-5 · Cited by 47
“, the proportion of surviving immunodeficient VAPP patients found to excrete long-term) [53].”
BackgroundInfluentialSelf-citationLaassri, M., Dragunsky, E., Enterline, J., Eremeeva, T., Ivanova, O., Lottenbach, K., Belshe, R., & Chumakov, K. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.6.2886-2894.2005 · Cited by 43
“Long-term persistence of poliovirus and its excretion by immunocompromised individuals (26, 32) suggest that some form of protection from the threat of reemergence of poliomyelitis may be needed even after the transmission of wild-type poliovirus has been eliminated.”
BackgroundGroup B Coxsackievirus Virulence
Tracy, S., & Gauntt, C. J. (2008) · Springer eBooks · doi:10.1007/978-3-540-75546-3_3 · Cited by 45
Shahmahmoodi, S., Parvaneh, N., Burns, C. C., Asghar, H., Mamishi, S., Tabatabaie, H., Chen, Q., Teimourian, S., Gooya, M. M., Esteghamati, A., et al. (2008) · Virus Research · doi:10.1016/j.virusres.2008.07.006 · Cited by 44
Self-citationOdoom, J. K., Yunus, Z., Dunn, G., Minor, P. D., & Martín, J. (2008) · Journal of Virology · doi:10.1128/jvi.00468-08 · Cited by 43
Adverse events following immunization in patients with primary immunodeficiencies
Delgado, J. S., Villada, F., Orrego, J. C., Franco, J. L., & Trujillo-Vargas, C. M. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.01.047 · Cited by 41
Poliovirus Vaccine Shedding among Persons with HIV in Abidjan, Cote d’Ivoire
Hennessey, K. A., Lago, H., Diomande, F., Akoua‐Koffi, C., Caceres, V. M., Pallansch, M. A., Kew, O. M., Nolan, M., & Zuber, P. L. F. (2005) · The Journal of Infectious Diseases · doi:10.1086/498166 · Cited by 39
Self-citationDriss, N., Ben‐Mustapha, I., Mellouli, F., Yahia, A. B., Touzi, H., Béjaoui, M., Ghorbel, M. B., Triki, H., & Barbouche, M. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00293-12 · Cited by 38
“The study population included 52 males and 30 females, ages 5 months to 33 years, diagnosed with 2 categories of PIDs: (i) humoral or combined immunodeficiencies (agammaglobulinemia, n 11; common variable immunodeficiency disorders [CVID], n 14; hyper-IgM syndrome, n 8; MHC class II deficiency, n 14) and (ii) other im…”
BackgroundInfluentialEnteroviruses and Parechoviruses
Dunn, J. J. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.dmih2-0006-2015 · Cited by 37
Can We Capitalize on the Virtues of Vaccines? Insights from the Polio Eradication Initiative
Aylward, R. B., & Heymann, D. L. (2005) · American Journal of Public Health · doi:10.2105/ajph.2004.055897 · Cited by 37
Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995–2014
Shaghaghi, M., Shahmahmoodi, S., Abolhassani, H., Soleymanjahi, S., Parvaneh, L., Mahmoudi, S., Chavoshzadeh, Z., Yazdani, R., Zahraei, S. M., Ebrahimi, M., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2210.151071 · Cited by 36
“In addition, patients with primary immunodeficiencies might shed VDPVs (immunodeficiency-associated VDPV [iVDPV]) in stool samples for an extended period after exposure to OPV strains (7).”
Backgroundde Silva, R., Gunasena, S., Ratnayake, D., Wickremesinghe, G. D., Kumarasiri, C., Pushpakumara, B. A. W., Deshpande, J. M., Kahn, A.-L., & Sutter, R. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.035 · Cited by 35
Self-citationBreman, J. G., de Quadrós, C. A., Dowdle, W. R., Foege, W. H., Henderson, D. A., John, T. J., & Levine, M. M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000405 · Cited by 35
“Modeling research is currently addressing the risks of virulent vaccine-derived poliovirus that may be chronically shed by immunodeficient individuals and from circulating vaccine-derived poliovirus, after OPV is withdrawn posteradication [70].”
BackgroundSutter, R. W., Kew, O. M., Cochi, S. L., & Aylward, R. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00048-1 · Cited by 33
Self-citationEvolution of a rare vaccine-derived multirecombinant poliovirus
Karakasiliοtis, I., Paximadi, E., & Markoulatos, P. (2005) · Journal of General Virology · doi:10.1099/vir.0.80823-0 · Cited by 33
“The presence of vaccine-derived polioviruses in immunodeficient patients (Bellmunt et al., 1999; Khetsuriani et al., 2003; MacLennan et al., 2004), civil sewage (Blomqvist et al., 2004; Vinje et al., 2004) or currently vaccinated populations clearly supports the existence of this problem.”
BackgroundShaghaghi, M., Parvaneh, N., Ostadrahimi, P., Fathi, S. M., Shahmahmoodi, S., Abolhassani, H., & Aghamohammadi, A. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.859156 · Cited by 32
“carry and excrete the vaccine-associated virus for a long time (immunodeficiency-related VDPV [iVDPV]), which could serve then as a possible reservoir for reintroducing the neurovirulent strains into the population (Khetsuriani et al., 2003).”
BackgroundNovel BTK mutation presenting with vaccine-associated paralytic poliomyelitis
Mamishi, S., Shahmahmoudi, S., Tabatabaie, H., Teimourian, S., Pourakbari, B., Gheisari, Y., Yeganeh, M., Salavati, A., Esteghamati, A., Gooya, M. M., et al. (2008) · European Journal of Pediatrics · doi:10.1007/s00431-008-0674-5 · Cited by 31
“Immunodeficient recipients of OPV are potentially predisposed to become long-term excretors of poliovirus vaccine strains (immunodeficiency-associated vaccinederived polioviruses [iVDPV]), with the possible risk of both developing paralysis and reintroducing reverted virulent poliovirus into the population after polio…”
BackgroundKhetsuriani, N., Helfand, R. F., Pallansch, M. A., Kew, O. M., Fowlkes, A., Oberste, M. S., Tukei, P. M., Muli, J., Makokha, E. P., & Gary, H. E. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-136 · Cited by 30
“To fully characterize the patterns of VDPV excretion among HIV-infected persons and to quantify the risk of long-term VDPV replication in this group, larger studies that cover the full range of HIV disease are needed.”
BackgroundInfluentialSelf-citationRiquet, F. B., Blanchard, C., Jegouic, S., Balanant, J., Guillot, S., Vibet, M.-A., Rakoto-Andrianarivelo, M., & Delpeyroux, F. (2008) · Journal of Virology · doi:10.1128/jvi.00239-08 · Cited by 29
Safety of Routine Childhood Vaccinations: An Epidemiological Review
Chen, R. T., Mootrey, G. T., & Destefano, F. R. (2000) · Pediatric Drugs · doi:10.2165/00128072-200002040-00004 · Cited by 29
Yan, D., Li, L., Zhu, S., Zhang, Y., An, J., Wang, D., Wen, N., Jorba, J. C., Liu, W. Y., Zhong, G., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00712-10 · Cited by 28
Self-citationCharacterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes
Puligedda, R. D., Kouiavskaia, D. V., Al‐Saleem, F. H., Kattala, C. D., Nabi, U., Yaqoob, H., Bhagavathula, V. S., Sharma, R., Chumakov, K., & Dessain, S. K. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.038 · Cited by 28
The global eradication of poliomyelitis: Progress and problems
Rey, M., & Girard, M. P. (2007) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2007.07.013 · Cited by 28
An approach to death as an adverse event following immunization
Gold, M., Balakrishnan, M. R., Amarasinghe, A., & MacDonald, N. E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.018 · Cited by 27
Foiadelli, T., Savasta, S., Battistone, A., Kota, M., Passera, C., Fiore, S., Bino, S., Amato, C., Lozza, A., Marseglia, G. L., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1587-y · Cited by 25
“In a small proportion of immunodeficient patients, Sabin strains can replicate in the intestine for several months or years [6–8], in contrast to the short (typically 3–4 weeks) period of replication in immunocompetent persons following their first OPV dose [9].”
BackgroundHuman monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains
Puligedda, R. D., Kouiavskaia, D. V., Adekar, S. P., Sharma, R., Kattala, C. D., Rezapkin, G. V., Bidzhieva, B., Dessain, S. K., & Chumakov, K. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.05.005 · Cited by 23
Highly Divergent Type 2 and 3 Vaccine-Derived Polioviruses Isolated from Sewage in Tallinn, Estonia
Al‐Hello, H., Jorba, J. C., Blomqvist, S., Raud, R., Kew, O. M., & Roivainen, M. (2013) · Journal of Virology · doi:10.1128/jvi.01174-13 · Cited by 22
“Unlike most individuals with iVDPV infections who either clear their infections or die within a year from complications of their immunodeficiency (8, 33), infected individuals with CVID may excrete iVDPVs for 5 years (13, 15, 16, 22).”
BackgroundSelf-citationRichie, M. B., & Pruitt, A. A. (2012) · Neurologic Clinics · doi:10.1016/j.ncl.2012.09.006 · Cited by 22
Shaghaghi, M., Shahmahmoodi, S., Nili, A., Abolhassani, H., Madani, S. P., Nejati, A., Yousefi, M., Kandelousi, Y. M., Irannejad, M., Shaghaghi, S., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2511.190540 · Cited by 21
“The genome of OPV strains is susceptible to spontaneous mutations because of its unstable structure, and the emergence of VDPVs threatens the whole eradication program (13).”
BackgroundZhao, K., Jorba, J. C., Shaw, J., Iber, J. C., Chen, Q., Bullard, K., Kew, O. M., & Burns, C. C. (2017) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2017.09.004 · Cited by 19
Self-citationMRI findings in an infant with vaccine-associated paralytic poliomyelitis
Ferraz-Filho, J. R. L., Torres, U. S., de Oliveira, E. P., & Souza, A. S. (2010) · Pediatric Radiology · doi:10.1007/s00247-010-1650-6 · Cited by 19
Romanenkova, N. I., Guillot, S., Rozaeva, N. R., Crainic, R., Bichurina, M. A., & Delpeyroux, F. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00017-06 · Cited by 16
“by on February 25, 2010 jcm.asm.org Downloaded from from the sequence of the original vaccine strain) for more than 1 year in patients with immunodeficiency has been reported in various countries (3, 8, 13, 21, 22 , 26, 27).”
BackgroundCommunity-Acquired Poliovirus Infection in Children with Primary Immunodeficiencies in Tunisia
Triki, H., Barbouche, M., Bahri, O., Béjaoui, M., & Dellagi, K. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.3.1203-1211.2003 · Cited by 17
Devaux, C. A., Pontarotti, P., Levasseur, A., Colson, P., & Raoult, D. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1284337 · Cited by 16
Vaccine-associated paralytic poliomyelitis in the Russian Federation in 1998–2014
Ivanova, O. E., Eremeeva, T. P., Morozova, N. S., Shakaryan, A. K., Korotkova, E. A., Kozlovskaya, L. I., Baykova, O. Y., Krasota, A. Y., & Gmyl, A. P. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.08.017 · Cited by 15
Kramer, L. (2004) · Wiener klinische Wochenschrift · doi:10.1007/bf03040699 · Cited by 15
Kindberg, E., Ax, C., Fiore, L., & Svensson, L. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21444 · Cited by 14
Luk, A. D. W., Ni, K., Wu, Y., Lam, K.-T., Chan, K. W., Lee, P. P. W., Tu, W., Mao, H., & Lau, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01826 · Cited by 13
Long-term virus evolution in nature
Domingo, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816331-3.00007-6 · Cited by 13
Introduction to the Human Enteroviruses and Parechoviruses
Romero, J. R., & Modlin, J. F. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00172-7 · Cited by 13
Shaghaghi, M., Irannejad, M., Abolhassani, H., Shahmahmoodi, S., Hamidieh, A. A., Soleymanjahi, S., Yazdani, R., Azizi, G., & Aghamohammadi, A. (2018) · Journal of Clinical Immunology · doi:10.1007/s10875-018-0521-z · Cited by 12
“Clearance of iVDPV infection after acute diarrheal illnesses has been reported in previous studies [4, 41].”
BackgroundResultInfluentialSullivan, K. E., Bassiri, H., Bousfiha, A. A., Costa‐Carvalho, B. T., Freeman, A. F., Hagin, D., Lau, Y., Lionakis, M. S., Moreira, I., Pinto, J. A., et al. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0426-2 · Cited by 11
Estívariz, C. F., Krow‐Lucal, E., & Mach, O. (2024) · Pathogens · doi:10.3390/pathogens13121128 · Cited by 10
Natural Clearance of Prolonged VDPV Infection in a Child With Primary Immunodeficiency Disorder
Mohanty, M. C., Madkaikar, M. R., Desai, M., Aluri, J., Varose, S. Y., Taur, P. D., Sharma, D. K., Nalavade, U. P., Rane, S. V., Gupta, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01567 · Cited by 10
“Patients with primary immunodeficiency (PID) are at ∼3,000-fold higher risks of developing VDPV infection (7, 8).”
BackgroundHassan, J., Wangai, L. N., Borus, P., Khayeka‐Wandabwa, C., Karani, L. W., Kithinji, M., & Kiptoo, M. K. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2843-y · Cited by 10
Okonko, I. O., Ogun, A. A., Adedeji, A. O., Akanbi, O. A., Udeze, A. O., & Motayo, B. O. (2009) · Scientific Research and Essays · doi:10.5897/sre.9000269 · Cited by 9
Kew, O. M. (2014) · Springer eBooks · doi:10.1007/978-1-4899-7448-8_13 · Cited by 9
Self-citationOkonko, I. O., Babalola, E. T., Adedeji, A. O., Onoja, A. B., Ogun, A. A., Nkang, A. O., & Adu, F. D. (2008) · Biotechnology and Molecular Biology Reviews · doi:10.5897/bmbr2008.0012 · Cited by 8
Weil, M., Rahav, G., Somech, R., Stauber, T., Alfandari, J., Weiss, L., Silberstein, I., Indenbaum, V., Or, I. B., Mendelson, E., et al. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.03.037 · Cited by 8
Toscana Virus and Acute Meningitis, France
Peyrefitte, C. N., Devetakov, I., Pastorino, B. A. M., Villeneuve, L., Bessaud, M., Stolidi, P., Depaquit, J., Segura, L., Gravier, P., Tock, F., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1105.040528 · Cited by 8
Romero, J. R., & Modlin, J. F. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00173-9 · Cited by 7
Vaccine–derived Poliovirus, Thailand, 2003
Tharmaphornpilas, P., for the Outbreak Response Team, & Thailand (2005) · Emerging infectious diseases · doi:10.3201/eid1105.0528 · Cited by 7
Costa‐Carvalho, B. T., Sullivan, K. E., Fontes, P. M., Nobre, F. A., Gonzales, I. G. S., Lima, E. S., Granato, C. F. H., & de Moraes‐Pinto, M. I. (2018) · Journal of Clinical Immunology · doi:10.1007/s10875-018-0531-x · Cited by 6
The Poliovirus Eradication Initiative
Chumakov, K., & Kew, O. M. (2014) · ASM Press eBooks · doi:10.1128/9781555816698.ch28 · Cited by 6
Self-citationAlirezaie, B., Taqavian, M., Aghaiypour, K., Esna‐Ashari, F., & Shafyi, A. (2011) · Journal of Medical Virology · doi:10.1002/jmv.21804 · Cited by 6
Khan, A. J., Gebreselassie, H., Asturias, E. J., Agboatwalla, M., Tekle‐Haimanot, R., Luby, S. P., Bayene, B., Chezzi, C., Asghar, H., Moatter, T., et al. (2006) · Biologicals · doi:10.1016/j.biologicals.2006.03.004 · Cited by 5
Self-citationSullivan, K. E., Bassiri, H., Bousfiha, A. A., Costa‐Carvalho, B. T., Freeman, A. F., Hagin, D., Lau, Y., Lionakis, M. S., Moreira, I., Pinto, J. A., et al. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0436-0 · Cited by 5
“Reports have shown that PIDD patients with antibody deficiency can have prolonged viral replication which can persist for years and therefore theoretically increase the risk for a spontaneous reversion within the immunodeficient host [249] [250] [251] [252] .”
BackgroundEnteroviruses and Parechoviruses
Dunn, J. J. (2016) · ASM Press eBooks · doi:10.1128/9781555819040.ch12 · Cited by 4
Estívariz, C. F., Burns, C. C., & Macklin, G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00050-5 · Cited by 4
Fan, Q., Ma, J., Li, X., Jorba, J. C., Yuan, F., Zhu, H., Hu, L., Song, Y., Wang, D., Zhu, S., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28215 · Cited by 3
“In contrast, in patients with immunodeficiency, VAPP risk is >3000‐fold higher than that in immunocompetent individuals.(13) Moreover, after OPV administration, the period of vaccine‐related PV infections is usually <2–3 months in immunocompetent individuals; however, the period can be prolonged to several months or y…”
Long-Term Virus Evolution in Nature
Domingo, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800837-9.00007-1 · Cited by 3
“Viral population numbers and the number of transmissible particles can be largely amplified in immunocompromised individuals, and have been termed super-spreaders; they can contribute large amounts of variant viruses to the transmission lottery (Rocha et al., 1991; Paunio et al., 1998; Gavrilin et al., 2000; Khetsuria…”
Poliomyelitis in modern conditions: achievements and prospects
Ivanova, O. E. (2018) · Journal Infectology · doi:10.22625/2072-6732-2018-10-2-17-29 · Cited by 3
Shulman, L. M., Weil, M., Somech, R., Stauber, T., Indenbaum, V., Rahav, G., Mendelson, E., & Sofer, D. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa053 · Cited by 2
Polio Today: State of the Global Eradication Program and Modern Strategy of WHO on Immunization
Ivanova, O. E. (2015) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2015-14-2-73-78 · Cited by 2
Modlin, J. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00171-5 · Cited by 1
Preventive Vaccination against Poliomyelitis: Modern View
Karpova, E. V., Sarkisyan, K. А., Movsesyants, A. A., & Меркулов, В. А. (2018) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2018-18-4-236-242 · Cited by 1
Metadata
- Authors
- Khetsuriani, N., Prevots, D. R., Quick, L., Elder, M. E., Pallansch, M., Kew, O., & Sutter, R. W.
- Affiliations
- Centers for Disease Control and Prevention (US)
- University of California, San Francisco (US)
- National Center for Infectious Diseases (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-15
- Volume
- 188
- Issue
- 12
- Pages
- 1845-1852
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2022472533
- Semantic Scholar
- 83fdf95068386f46d83baefa084cdf25850c5eec
- Cited by
- 110
- References
- 18
- Citations by year
- 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 7 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 6 · 2013: 4 · 2012: 7
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- vaccine-derived poliovirus, vaccine-associated paralytic poliomyelitis, immunodeficient patients, polio eradication, virological surveillance
- MeSH terms
- Feces, Female, Follow-Up Studies, Humans, Immunologic Deficiency Syndromes, Infant, Male, Poliomyelitis, Poliovirus Vaccine, Oral, Surveys and Questionnaires, Retrospective Studies, United States, Vaccination, Genetic Variation, Program Evaluation, Genome, Viral, Immunization Programs, Poliovirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.